NR4A1 and breast cancer: These compounds typically displayed the strongest activity against MDA-MB-468 (triple negative) and MCF-7 (hormone receptor-positive, HER2 negative) and weakest activity against HS578T (triple negative), suggesting that their activity may not be linked to specific breast cancer subtypes.